Marked tumor response and fatal hemoptysis during radiation for lung cancer in a human immunodeficiency virus-positive patient taking nelfinavir

Journal of Thoracic Oncology

Volumn 4, Issue 12, 2009, Pages 1587-1589

  Chapman, Christopher H ^a   Shen, John ^a   Filion, Edith J ^a,b   Tran, Phuoc T ^a   Hara, Wendy ^a   Asuncion, Alfredo ^c   Marko, Daniel ^d   Wakelee, Heather ^e   Berry, Gerald J ^a   Loo Jr , Billy W ^a   Green, Jon ^c   Dimmick, Kevin W ^f  

^a STANFORD UNIVERSITY   (United States)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c VA NORTHERN CALIFORNIA HEALTH CARE SYSTEM   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Stanford Medicine Children s Health   (United States)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; NELFINAVIR; RADIOSENSITIZING AGENT;

ARTICLE; AUTOPSY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CASE REPORT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG DOSE INCREASE; HEMOPTYSIS; HISTOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LUNG HEMORRHAGE; LUNG PARENCHYMA; LUNG SQUAMOUS CELL CARCINOMA; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION INJURY; TREATMENT PLANNING; TUMOR REGRESSION; TUMOR VOLUME;

EID: 74249111862     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181bf111d     Document Type: Article

References (7)

1. Albain KS, Swann RS, Rusch VR, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 2009;374:379-386.
2. Plastaras JP, Vapiwala N, Ahmed MS, et al. Validation and toxicity of PI3K/Akt pathway inhibition by HIV protease inhibitors in humans. Cancer Biol Ther 2008;7:628-635.
3. Brunner TB, Geiger M, Grabenbauer GG, et al. Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer. J Clin Oncol 2008;26:2699-2706.
4. Tatum JL, Kelloff GJ, Gillies RJ, et al. Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol 2006;82:699-757.
5. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58-62.
6. Pore N, Gupta AK, Cerniglia GJ, et al. Nelfinavir down-regulates hypoxia-inducible factor 1alpha and VEGF expression and increases tumor oxygenation: implications for radiotherapy. Cancer Res 2006;66: 9252-9259.
7. Sandler AB, Schiller JH, Gray R, et al. Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab. J Clin Oncol 2009;27:1405-1412.